Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease
Status:
Completed
Trial end date:
2016-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the ability of peginesatide (AF37702) to increase
and maintain increased hemoglobin levels in participants with chronic kidney disease (CKD)
(either not on dialysis, receiving regular hemodialysis or peritoneal dialysis, or following
renal transplant) with confirmed antibody-mediated pure red cell aplasia (PRCA).